Trial Profile
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Nebilet Administered in Korean Patients According to the Prescribing Information.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Nebivolol (Primary)
- Indications Heart failure; Hypertension
- Focus Adverse reactions
- Sponsors GSK
- 14 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Mar 2010 New trial record